InsidersTradesSigma
Total declarations
Company
▲ Purchases (47 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
47
Disclosed sells
0
T+90 hit rate
33%
T+90 mean return
-18.6%
Across 30 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Altman Peter, Chairman & CEO. Insider active across 1 company, notably BioCardia, Inc.. Cumulatively, 63 reports have been logged. Breakdown: 47 buys · 0 sell. Total volume traded: €265k. History available since 10 June 2021. The latest transaction was disclosed on 2 July 2026 (Retenue fiscale). Regulator: SEC (Form 4). All data is free.
Declarations63 total
54,606 shares@ US$1.24Common StockSEC:0001437749-26-022969:0
110,625 sharesCommon StockSEC:0001437749-26-022365:0
1,500 sharesCommon StockSEC:0001437749-26-021216:0
Ideal exit: 14 Mar 2027 (T+270)
800 sharesCommon StockSEC:0001437749-26-021216:1
Ideal exit: 15 Mar 2027 (T+270)
5,000 sharesCommon StockSEC:0001437749-26-020044:0
Ideal exit: 6 Mar 2027 (T+270)
200 shares@ US$0.950.0015% mcap0.0% of flowCommon StockSEC:0001437749-26-018125:0
Ideal exit: 13 Feb 2027 (T+270)
1,500 shares@ US$0.920.011% mcap0.1% of flowCommon StockSEC:0001437749-26-018125:1
Ideal exit: 14 Feb 2027 (T+270)
5,100 shares@ US$1.020.040% mcap2.5% of flowCommon StockSEC:0001437749-26-017459:0
Ideal exit: 9 Feb 2027 (T+270)
5,100 shares@ US$1.020.029% mcap0.5% of flowCommon StockSEC:0001437749-26-017459
Ideal exit: 9 Feb 2027 (T+270)
5,000 shares@ US$1.11Common StockSEC:0001437749-26-013944:0
Ideal exit: 24 Jan 2027 (T+270)
48,000 shares@ US$1.255.5% of flowCommon StockSEC:0001437749-25-029651:0
Ideal exit: 16 Jun 2026 (T+270)
400 shares@ US$1.7510.1% of flowCommon StockSEC:0001437749-25-026308:0
Ideal exit: 9 May 2026 (T+270)
100 shares@ US$2.210.0% of flowCommon StockSEC:0001437749-25-019036:0
Ideal exit: 24 Feb 2026 (T+270)
1,600 shares@ US$2.080.3% of flowCommon StockSEC:0001437749-25-018235:0
Ideal exit: 14 Feb 2026 (T+270)
100 shares@ US$2.9860.0% of flowCommon StockSEC:0001437749-25-017469:0
Ideal exit: 8 Feb 2026 (T+270)
26,246 shares@ US$1.9054.8% of flowCommon StockSEC:0001437749-25-013196:0
Ideal exit: 18 Jan 2026 (T+270)
100 shares@ US$2.140.0% of flowCommon StockSEC:0001437749-25-012314:0
Ideal exit: 10 Jan 2026 (T+270)
300 shares@ US$1.990.1% of flowCommon StockSEC:0001437749-25-011966:0
Ideal exit: 5 Jan 2026 (T+270)
500 shares@ US$1.960.1% of flowCommon StockSEC:0001437749-25-011432:0
Ideal exit: 2 Jan 2026 (T+270)
800 shares@ US$2.040.2% of flowCommon StockSEC:0001437749-25-011212:0
Ideal exit: 30 Dec 2025 (T+270)
500 shares@ US$2.230.1% of flowCommon StockSEC:0001437749-25-011045:0
Ideal exit: 28 Dec 2025 (T+270)
1,200 shares@ US$2.240.3% of flowCommon StockSEC:0001437749-25-010953:0
Ideal exit: 29 Dec 2025 (T+270)
500 shares@ US$2.110.1% of flowCommon StockSEC:0001437749-25-006016:0
Ideal exit: 28 Nov 2025 (T+270)
600 shares@ US$2.480.2% of flowCommon StockSEC:0001437749-25-003441:0
Ideal exit: 4 Nov 2025 (T+270)
500 shares@ US$2.400.1% of flowCommon StockSEC:0001437749-25-002318:0
Ideal exit: 26 Oct 2025 (T+270)
25 of 63 declarations
About Altman Peter
Public sources indicate that Peter A. Altman, Ph.D., has served as President and CEO of BioCardia since 2002. BioCardia also states that he was a CareDx CEO from 1999 to 2003 and a board member there from 1999 to 2014, and that he served as CEO of Lumen Therapeutics from 2004 to 2005. The company says he is named inventor on 45 U.S. patents, has authored 40 scientific publications, and earned a Ph.D. in bioengineering/pharmaceutical chemistry from the University of California, San Francisco and the University of California, Berkeley. Sources: https://www.biocardia.com/about-us/management-team/peter-a-altman/id/15
